转甲状腺素蛋白淀粉样变心肌病中左心房结构与功能、临床结局及Vutrisiran疗效:HELIOS-B随机临床试验二次分析
该研究为HELIOS-B三期随机试验的二次分析,纳入655例ATTR-CM患者,中位随访36个月。结果显示左心房应变(LASr、LASct)独立关联全因死亡、复发性心血管事件、心衰住院及新发房颤,而左房容积指数无此关联;Vutrisiran在30个月时减轻左房应变恶化。
要点
- ATTR-CM患者左房应变显著低于正常,LASr均值9.5%。
- LASr和LASct独立预测全因死亡、复发性心血管事件及新发房颤。
- Vutrisiran在30个月时减轻左房应变恶化,且基线应变不影响其疗效。
核心结论
- ATTR-CM患者左房功能障碍常见且提示预后更差。
- Vutrisiran在30个月时减轻左房应变恶化,支持左房功能在ATTR-CM病理生理中的重要性。
研究设计与样本
- 共655例入组,644例可测左房应变,中位随访36个月。
主要发现
- 可测左房应变患者中位年龄77岁,女性48例(7.5%),野生型ATTR 569例(88.4%)。
- 左房应变均值显著低于正常:LASr 9.5%(SD 6.0%),LAScd 6.9%(SD 3.9%),LASct 4.2%(SD 4.0%)。
关键数值与推荐
- Vutrisiran 25 mg皮下注射每3个月一次,对照安慰剂。
- 30个月时Vutrisiran较安慰剂减轻左房应变恶化:LASr +1.2%(95%CI +0.4%至+1.9%),LAScd +0.8%(95%CI +0.3%至+1.4%),LASct +0.8%(95%CI 0%至+1.6%)。
临床怎么用
- 左房应变(LASr、LASct)可用于ATTR-CM风险分层,预测死亡、心衰住院及新发房颤。
- Vutrisiran治疗可减缓左房心肌病进展,支持早期启动沉默疗法。
局限性
- 本研究为事后二次分析,结果需进一步验证。
- 左房应变测量仅在部分患者(644/655)中可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Left atrial (LA) dysfunction may play an important role in the pathophysiology of transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and is driven by LA remodeling and amyloid infiltration. OBJECTIVES: To evaluate the prognostic significance of LA structure and function among patients with ATTR-CM and to assess the effects of vutrisiran on these parameters. DESIGN, SETTING, AND PARTICIPANTS: Post hoc analyses were conducted of the HELIOS-B phase 3 randomized clinical trial, which enrolled patients with ATTR-CM between December 2019 and August 2021 at 87 sites in 26 countries. Median (IQR) follow-up was 36 (33-36) months. Data were analyzed from July through November 2025. INTERVENTIONS: Vutrisiran (25 mg subcutaneously every 3 months) vs placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality (ACM) and recurrent cardiovascular events. LA structure (LA volume index [LAVi]) and function (LA reservoir [LASr], conduit [LAScd], and contractile strain [LASct]) were assessed, including the effect of vutrisiran on these measures at 30 months. RESULTS: A total of 655 patients were enrolled. Among 644 patients with measurable LA strain (median [IQR] age, 77 [72-80] years; 48 female patients [7.5%]; 569 (88.4%) with wild-type ATTR), mean (SD) LA strain measures were substantially below normal (LASr: 9.5% [6.0%]; LAScd: 6.9% [3.9%]; LASct: 4.2% [4.0%]). Patients with worse LASr had more advanced disease, more atrial fibrillation, and more left ventricular systolic and diastolic dysfunction. LASr and LASct were independently associated with ACM and recurrent cardiovascular events (LASr: hazard ratio [HR] per 5% worsening, 1.37; 95% CI, 1.13-1.68; P = .002; LASct: HR per 5% worsening, 1.53; 95% CI, 1.08-2.17; P = .02), recurrent heart failure hospitalizations (LASr: HR, 1.66; 95% CI, 1.22-2.25; P = .001; LASct: HR, 2.23; 95% CI. 1.46-3.71; P < .001), and incident atrial fibrillation (LASr: HR, 1.30; 95% CI, 1.03-1.63; P = .03; LASct: HR, 2.02; 95% CI, 1.38-2.96; P < .001). In contrast, LAVi was not associated with these outcomes. LA strain measures at baseline did not modify the treatment effect of vutrisiran on ACM and recurrent cardiovascular events (LASr: P value for interaction = .60; LAScd: P value for interaction = .58; LASct: P value for interaction = .47). Vutrisiran attenuated worsening in LA strain vs placebo at month 30 (LASr: +1.2%; 95% CI, +0.4% to +1.9%; LAScd: +0.8%; 95% CI, +0.3% to +1.4%; LASct: +0.8%; 95% CI, 0% to +1.6%). CONCLUSIONS AND RELEVANCE: Per the results of this secondary analysis of the HELIOS-B randomized clinical trial, LA dysfunction is common among patients with ATTR-CM and portends a worse prognosis. Consistent with its beneficial effects on other measures of cardiac structure and function, vutrisiran attenuated worsening in LA strain at 30 months, supporting the importance of LA function in the pathophysiology of ATTR-CM and the ability of silencer therapy with vutrisiran to attenuate worsening atrial myopathy in amyloid heart disease. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04153149.
引用
- Jering KS, Manafi A, Claggett BL, et al. Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42616515. doi:10.1001/jamacardio.2026.2992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。